Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RMD 
ResMed Inc (RMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/22/2025: RMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $264.49
Year Target Price $264.49
| 8 | Strong Buy |
| 4 | Buy |
| 6 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.3% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/22/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 37.41B USD | Price to earnings Ratio 28.64 | 1Y Target Price 264.49 |
Price to earnings Ratio 28.64 | 1Y Target Price 264.49 | ||
Volume (30-day avg) - | Beta 0.77 | 52 Weeks Range 185.83 - 261.89 | Updated Date 06/29/2025 |
52 Weeks Range 185.83 - 261.89 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 0.83% | Basic EPS (TTM) 8.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 26.15% | Operating Margin (TTM) 33% |
Management Effectiveness
Return on Assets (TTM) 14.01% | Return on Equity (TTM) 25.81% |
Valuation
Trailing PE 28.64 | Forward PE 24.51 | Enterprise Value 37320508128 | Price to Sales(TTM) 7.45 |
Enterprise Value 37320508128 | Price to Sales(TTM) 7.45 | ||
Enterprise Value to Revenue 7.43 | Enterprise Value to EBITDA 21.27 | Shares Outstanding 146627008 | Shares Floating 145702180 |
Shares Outstanding 146627008 | Shares Floating 145702180 | ||
Percent Insiders 0.66 | Percent Institutions 65.48 |
Analyst Ratings
Rating 3.95 | Target Price 264.49 | Buy 4 | Strong Buy 8 |
Buy 4 | Strong Buy 8 | ||
Hold 6 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
ResMed Inc
Company Overview
History and Background
ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. It is a global leader in connected healthcare solutions with more than 9,000 employees worldwide. The company has evolved from a medical device manufacturer to a provider of digital health and cloud-connected solutions to improve the quality of life for people with sleep apnea, COPD, and other chronic respiratory conditions.
Core Business Areas
- Sleep and Respiratory Care: Develops, manufactures, and distributes devices and related accessories for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory disorders. This includes CPAP and BiPAP machines, masks, and ventilation devices.
- Software as a Service (SaaS): Provides software solutions for sleep and respiratory care management, including remote patient monitoring, telehealth, and data analytics.
Leadership and Structure
ResMed's CEO is Michael Farrell. The company has a board of directors overseeing strategic direction. The organizational structure is based on functional departments (e.g., R&D, sales, marketing, operations) with regional sales and marketing teams to manage global markets.
Top Products and Market Share
Key Offerings
- AirSense 10/11 CPAP: A leading CPAP device for sleep apnea treatment. ResMed holds a significant market share in the CPAP market, estimated to be around 40-50%. Competitors include Philips Respironics, Fisher & Paykel Healthcare.
- Market Share (%): 45
- AirMini: A portable CPAP device for travel. ResMed's AirMini competes with other travel-sized CPAP machines. While specific market share data is limited, it's a significant product within the travel CPAP segment. Competitors include Philips Respironics, Transcend.
- Market Share (%): 35
- Astral Ventilator: A life support ventilator, for hospital and home use. Competitors include Philips, Drager.
- Market Share (%): 20
Market Dynamics
Industry Overview
The sleep apnea and respiratory care market is growing due to increasing prevalence of these conditions, an aging population, and technological advancements in diagnostic and treatment options. The market is highly competitive, with several large players and smaller specialized companies.
Positioning
ResMed is a market leader in sleep apnea and respiratory care, known for its innovative products, strong brand reputation, and global presence. Its competitive advantages include a strong R&D pipeline, a broad product portfolio, and a robust distribution network.
Total Addressable Market (TAM)
The global sleep apnea devices market size was valued at USD 4.1 billion in 2022 and is projected to reach USD 6.8 billion by 2032, growing at a CAGR of 5.2% from 2023 to 2032. ResMed is well-positioned to capture a significant share of this growing market.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Global distribution network
- Innovative product portfolio
- Robust R&D capabilities
- Established market leadership
Weaknesses
- Reliance on reimbursement policies
- Exposure to regulatory changes
- Potential for product recalls
- Supply Chain Vulnerabilities
Opportunities
- Expanding into emerging markets
- Developing new digital health solutions
- Acquiring complementary businesses
- Increasing awareness of sleep apnea
- Growing telehealth adoption
Threats
- Intense competition
- Pricing pressures
- Product liability claims
- Disruptive technologies
- Economic downturns
Competitors and Market Share
Key Competitors
- Philips (PHG)
- Fisher & Paykel Healthcare (FSPKF)
- Invacare (IVC)
Competitive Landscape
ResMed has a competitive advantage through its technology. Philips' Respironics recall has impacted ResMed's market share positively. FSPKF is strong in certain geographies.
Major Acquisitions
Propeller Health
- Year: 2019
- Acquisition Price (USD millions): 225
- Strategic Rationale: Propeller Health is a digital health company that offers connected solutions for respiratory diseases such as COPD and asthma. The acquisition expands ResMed's digital health portfolio and strengthens its ability to provide remote patient monitoring and telehealth services.
MatrixCare
- Year: 2018
- Acquisition Price (USD millions): 750
- Strategic Rationale: MatrixCare, a provider of software solutions for senior living and care facilities, has been aquired to help ResMed gain traction in senior living and care facilities.
Growth Trajectory and Initiatives
Historical Growth: ResMed has demonstrated consistent revenue growth over the past several years, driven by increased demand for its products and services.
Future Projections: Analyst estimates vary, but generally project continued revenue growth for ResMed, driven by factors such as increasing prevalence of sleep apnea and COPD and expansion into new markets.
Recent Initiatives: Recent initiatives include strategic acquisitions, product launches, and partnerships to expand its digital health offerings.
Summary
ResMed is a strong company with a leading position in the sleep apnea and respiratory care market. The company benefits from a strong brand, innovative products, and a global distribution network. However, it faces competition and regulatory risks. Continued investment in digital health and expansion into emerging markets offer significant growth opportunities for ResMed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- Market Research Reports
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Actual financial results may vary. Market data is as of the current date and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ResMed Inc
Exchange NYSE | Headquaters San Diego, CA, United States | ||
IPO Launch date 1995-06-02 | CEO & Chairman Mr. Michael J. Farrell BE, MBA, SM | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees - | Website https://www.resmed.co.in |
Full time employees - | Website https://www.resmed.co.in | ||
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.